Characterization of tumefactive demyelinating lesions using MR imaging and in-vivo proton MR spectroscopy

Abstract

Background and Objectives

Diagnosis of tumefactive demyelinating lesions (TDLs) is challenging to both clinicians and radiologists. Our objective in this study was to analyze and characterize these lesions clinically, biochemically, electrophysiologically, and on imaging.

Methods

A retrospective analysis with prospective follow-up of 18 cases of TDLs was performed. Imaging included T2-, T1-weighted, fluid-attenuated inversion recovery (FLAIR), post-contrast T1-weighted, diffusion weighted imaging (DWI), and proton magnetic resonance spectroscopy (PMRS).

Results

All the lesions appeared hyperintense on T2 and FLAIR images. Increased Apparent diffusion coefficient (ADC) (0.93–2.21 × 10⁻³ mm²/s) in centre of the lesion was seen in 14/18 cases; however, peripheral restriction (ADC values 0.55–0.64 × 10⁻³ mm²/s) was noted in 11/18 cases. In all, 13/18 cases showed contrast enhancement with open ring (n = 5), complete ring (n = 1), minimal (n = 4), and infiltrative (n = 3) pattern of enhancement. Nine of these 13 cases also showed venular enhancement. On PMRS, nine showed glutamate/glutamine (Glx) at 2.4 ppm.

Conclusion

Clinical features along with several MRI characteristics such as open ring enhancement, peripheral restriction on DWI, venular enhancement, and presence of Glx on spectroscopy may be rewarding in differentiating TDLs from neoplastic lesions.

Keywords

apparent diffusion coefficient diffusion weighted imaging glutamate magnetic resonance imaging proton magnetic resonance spectroscopy tumefactive demyelinating lesions

Get full access to this article

View all access options for this article.

References

1 Dagher AP Smirniotopoulos J . Tumefactive demyelinating lesions. Neuroradiology 1996; 38: 560–565.

2 Kepes JJ . Large focal tumor-like demyelinating lesions of the brain: intermediate entity between multiple sclerosis and acute disseminated encephalomyelitis? A study of 31 patients. Ann Neurol 1993; 33: 18–27.

3 Hunter SB Ballinger WE Rubin JJ . Multiple sclerosis mimicking primary brain tumor. Arch Pathol Lab Med 1987; 111: 464–468.

4 Giang DW Poduri KR Eskin TA . Multiple sclerosis masquerading as a mass lesion. Neuroradiology 1992; 34: 150–154.

5 Kurihara N Takahashi S Furuta A . MR imaging of multiple sclerosis simulating brain tumor. Clin Imaging 1996; 20: 171–177.

6 Zagzag D Miller DC Kleinman GM Abati A Donnenfeld H Budzilovich GN . Demyelinating disease versus tumor in surgical neuropathology: clues to a correct pathological diagnosis. Am J Surg Pathol 1993; 17: 537–545.

7 Saindane AM Cha S Law M Xue X . knopp EA, Zagzag, D. Proton MR spectroscopy of tumefactive demyelinating lesions. AJNR 2002; 23: 1378–1386.

8 Given CA Stevens BS Lee C . The MRI appearance of tumefactive demyelinating lesions. AJR Am J Roentgenol 2004; 182: 195–199.

9 Cha S Pierce S Knopp EA . Dynamic contrast-enhanced T2-weighted MR imaging of tumefactive demyelinating lesions. AJNR 2001; 22: 1109–1116.

10.

10 Paley RJ Persing JA Doctor A Westwater JJ Roberson JP Edlich RF . Multiple sclerosis and brain tumor: a diagnostic challenge. J Emerg Med 1989; 7: 241–244.

11.

11 Polman CH Reingold SC Edan G . Diagnostic criteria for Multiple Sclerosis: 2005 Revisions to the “McDonald Criteria”. Ann Neurol 2005; 58: 840–846.

12.

12 Sinha S Thomas MA Huda AS Lufkin RB . Magnetic resonance imaging and spectroscopic imaging. In: RK Gupta BR Lufkin , (eds), MR imaging and spectroscopy of central nervous system infection. Kluver Press, New York: 2001. p. 1–57.

13.

13 Ernst T Chang L Walot I Huff K . Physiologic MRI of tumefactive multiple sclerosis lesion. Neurology 1998; 51: 1486–1488.

14.

14 Metafratzi Z Argyropoulou MI Tzoufi M Papadopoulou Z Efremidis SC . Conventional MRI and magnetization transfer imaging of tumor-like multiple sclerosis in a child. Neuroradiology 2002; 44: 97–99.

15.

15 Akimoto J Nakajima N Saida A Haraoka J Kudo M . Monofocal acute inflammatory demyelination manifesting as open ring sign. Case report. Neurol Med Chir (Tokyo) 2006; 46: 353–357.

16.

16 Bernarding J Braun J Koennecke HC . Diffusion-and perfusion-weighted MR imaging in a patient with acute demyelinating encephalomyelitis (ADEM). J Magn Reson Imaging 2002; 15: 96–100.

17.

17 Tievsky AL Ptak T Farkas J . Investigation of apparent diffusion coefficient and diffusion tensor anisotropy in acute and chronic multiple sclerosis lesions. AJNR Am J Neuroradiol 1999; 20: 1491–1499.

18.

18 Rovaris M Gass A Bammer R . Diffusion MRI in multiple sclerosis. Neurology 2005; 65: 1526–1532.

19.

19 Gass A Niendorf T Hirsch JG . Acute and chronic changes of the apparent diffusion coefficient in neurological disorders-biophysical mechanisms and possible underlying histopathology. J Neurol Sci 2001; 186: 15–23.

20.

20 Desprechins B Stadnik T Koerts G Shabana W Breucq C Osteaux M . Use of diffusion weighted MR imaging in differential diagnosis between intracerebral necrotic tumors and cerebral abscesses. AJNR Am J Neuroradiol 1999; 20: 1252–1257.

21.

21 Noguchi K Watanabe N Nagayoshi T . Role of diffusion weighted echo-planar MRI in distinguishing between brain abscess and tumour: a preliminary report. Neuroradiology 1999; 41: 171–174.

22.

22 Tung G Evangelista P Rogg J Duncan JI . Diffusion-weighted MR imaging of rim-enhancing brain masses: is markedly decreased water diffusion specific for brain abscess? AJR Am J Roentgenol 2001; 177: 709–712.

23.

23 Prineas JW McDonald WI . Demyelinating diseases. Greenfield's Neuropathology. Vol. 1. 6th ed. New York: Wiley; 1997. p. 814–846.

24.

24 Adams C . Vascular aspects of multiple sclerosis. A colour atlas of multiple sclerosis and other myelin disorders. London: Wolfe. Medical Publications 1989; p. 184–187.

25.

25 Cianfoni A Niku S Imbesi SG . Metabolite findings in tumefactive demyelinating lesions utilizing short echo time proton magnetic resonance spectroscopy. AJNR 2007; 28: 272–277.

26.

26 Danielsen ER Ross B . The clinical significance of metabolites. In: Danielsen, ER, Ross, B (eds), Magnetic resonance spectroscopy diagnosis of neurological diseases. New York: Marcel Dekker; 1999. p. 23–43.

27.

27 Saindane AM Cha S Law M Xue X . knopp EA, Zagzag, D. Proton MR Spectroscopy of tumefactive demyelinating lesions. AJNR 2002; 23: 1378–1386.

28.

28 Law M Meltzer DE Cha S . Spectroscopic magnetic resonance imaging of tumefactive demyelinating lesion. Neuroradiology 2002; 44: 986–989.

29.

29 Youl BD Kermode AF Thompson AJ . Destructive lesions in demyelinating disease. J Neurol Neurosurg Psychiatry 1991; 54: 288–292.

30.

30 Nesbit GM Forbes GS Scheithauer BW Okazaki H Rodriguez H . Multiple Sclerosis: Histopathologic and MR and/or CT correlation in 37 cases at biopsy and three cases at autopsy. Radiology 1991; 180: 467–474.

31.

31 Sugita Y Terasaki M Shigemori M Sakata K Morimatsu M . Acute focal demyelinating disease simulating brain tumors: histopathologic guidelines for an accurate diagnosis. Neuropathology 2001; 21: 25–31.

32.

32 Lucchinetti CF Gavrilova RH Metz I . Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain 2008; 131: 1759–1775.